BACKGROUND: Although correlations between cervical cytologic status and both human papillomavirus (HPV) load and histopathologic status are recognized, it is largely undetermined whether the association between the HPV DNA load and the risk of cervical intraepithelial neoplasia grade 3 (CIN-3) differs on the basis of cervical cytologic findings. METHODS: Study subjects were 821 women enrolled in the ASCUS-LSIL Triage Study who tested positive for HPV-16 at entry. Women were followed semiannually for 2 years. The baseline HPV-16 load was measured by real-time polymerase chain reaction. RESULTS: CIN-3 was confirmed in 286 (34.8%) of 821 women during the 2-year follow-up period. The adjusted odds ratio (OR) of the 2-year cumulative risk of CIN-3 was 1.46 (95% confidence interval [CI], 1.29-1.64) per 1 log(10) increase in virus load. The ORs varied from 1.66 (95% CI, 1.16-2.37) for women with normal cytologic findings at enrollment to 0.86 (95% CI, 0.61-1.20) for those with high-grade squamous intraepithelial lesions. Among women with normal cytologic findings at enrollment, the area under the receiver operating characteristic curve for detection of CIN-3 on the basis of the virus load was 0.70 (95% CI, 0.61-0.78). CONCLUSION: The HPV-16 DNA load was associated with the risk of developing CIN-3, but the associations varied with cytologic findings at the time of virus load measurement. The clinical usefulness of measuring the HPV-16 load as a means to detect CIN-3 was minimal, even in women with normal cytologic findings.
BACKGROUND: Although correlations between cervical cytologic status and both human papillomavirus (HPV) load and histopathologic status are recognized, it is largely undetermined whether the association between the HPV DNA load and the risk of cervical intraepithelial neoplasia grade 3 (CIN-3) differs on the basis of cervical cytologic findings. METHODS: Study subjects were 821 women enrolled in the ASCUS-LSIL Triage Study who tested positive for HPV-16 at entry. Women were followed semiannually for 2 years. The baseline HPV-16 load was measured by real-time polymerase chain reaction. RESULTS:CIN-3 was confirmed in 286 (34.8%) of 821 women during the 2-year follow-up period. The adjusted odds ratio (OR) of the 2-year cumulative risk of CIN-3 was 1.46 (95% confidence interval [CI], 1.29-1.64) per 1 log(10) increase in virus load. The ORs varied from 1.66 (95% CI, 1.16-2.37) for women with normal cytologic findings at enrollment to 0.86 (95% CI, 0.61-1.20) for those with high-grade squamous intraepithelial lesions. Among women with normal cytologic findings at enrollment, the area under the receiver operating characteristic curve for detection of CIN-3 on the basis of the virus load was 0.70 (95% CI, 0.61-0.78). CONCLUSION: The HPV-16 DNA load was associated with the risk of developing CIN-3, but the associations varied with cytologic findings at the time of virus load measurement. The clinical usefulness of measuring the HPV-16 load as a means to detect CIN-3 was minimal, even in women with normal cytologic findings.
Authors: J Cuzick; A Szarewski; H Cubie; G Hulman; H Kitchener; D Luesley; E McGoogan; U Menon; G Terry; R Edwards; C Brooks; M Desai; C Gie; L Ho; I Jacobs; C Pickles; P Sasieni Journal: Lancet Date: 2003-12-06 Impact factor: 79.321
Authors: Mark E Sherman; Sophia S Wang; Cosette M Wheeler; Laurie Rich; Patti E Gravitt; Robert Tarone; Mark Schiffman Journal: Cancer Epidemiol Biomarkers Prev Date: 2003-10 Impact factor: 4.254
Authors: Thomas C Wright; Mark Schiffman; Diane Solomon; J Thomas Cox; Francisco Garcia; Sue Goldie; Kenneth Hatch; Kenneth L Noller; Nancy Roach; Carolyn Runowicz; Debbie Saslow Journal: Obstet Gynecol Date: 2004-02 Impact factor: 7.661
Authors: André Luis Santos; Sophie Françoise Derchain; Marcos Roberto Martins; Luís Otávio Sarian; Edson Zangiacome Martinez; Kari Juhani Syrjänen Journal: Sao Paulo Med J Date: 2004-06-28 Impact factor: 1.044
Authors: Long Fu Xi; Mark Schiffman; James P Hughes; Denise A Galloway; Laura A Koutsky; Nancy B Kiviat Journal: Cancer Epidemiol Biomarkers Prev Date: 2019-05-17 Impact factor: 4.254
Authors: Xia Liu; Mark Schiffman; Ayaka Hulbert; Zhonghu He; Zhenping Shen; Laura A Koutsky; Long Fu Xi Journal: J Clin Microbiol Date: 2015-08-19 Impact factor: 5.948
Authors: Long Fu Xi; James P Hughes; Philip E Castle; Zoe R Edelstein; Chunhui Wang; Denise A Galloway; Laura A Koutsky; Nancy B Kiviat; Mark Schiffman Journal: J Infect Dis Date: 2011-03-16 Impact factor: 5.226
Authors: Long Fu Xi; Laura A Koutsky; Philip E Castle; Cosette M Wheeler; Denise A Galloway; Constance Mao; Jesse Ho; Nancy B Kiviat Journal: J Natl Cancer Inst Date: 2009-01-27 Impact factor: 13.506
Authors: Rachel L Winer; Tiffany G Harris; Long Fu Xi; Kathrin U Jansen; James P Hughes; Qinghua Feng; Carolee Welebob; Jesse Ho; Shu-Kuang Lee; Joseph J Carter; Denise A Galloway; Nancy B Kiviat; Laura A Koutsky Journal: J Med Virol Date: 2009-04 Impact factor: 2.327
Authors: Long Fu Xi; Laura A Koutsky; Philip E Castle; Zoe R Edelstein; Craig Meyers; Jesse Ho; Mark Schiffman Journal: Cancer Epidemiol Biomarkers Prev Date: 2009-12 Impact factor: 4.254
Authors: Long Fu Xi; Zoe R Edelstein; Craig Meyers; Jesse Ho; Stephen L Cherne; Mark Schiffman Journal: Cancer Epidemiol Biomarkers Prev Date: 2009-08-18 Impact factor: 4.254
Authors: Mary K Grabowski; Xiangrong Kong; Ronald H Gray; David Serwadda; Godfrey Kigozi; Patti E Gravitt; Fred Nalugoda; Steven J Reynolds; Maria J Wawer; Andrew D Redd; Stephen Watya; Thomas C Quinn; Aaron A R Tobian Journal: J Infect Dis Date: 2015-11-23 Impact factor: 5.226
Authors: Long Fu Xi; James P Hughes; Zoe R Edelstein; Nancy B Kiviat; Laura A Koutsky; Constance Mao; Jesse Ho; Mark Schiffman Journal: J Infect Dis Date: 2009-12-01 Impact factor: 5.226